That’s the title of a KFF article printed final week. The outcomes are based mostly on KFF’s 2024 Employer Well being Advantages Survey. They write:
For KFF’s survey of two,142 randomly chosen firms, officers from these with 500 or extra staff had been requested how a lot of the rebates negotiated by [pharmacy benefit managers] PBMs returned to the corporate as financial savings. About 19% mentioned they obtained a lot of the rebates, 27% mentioned some, and 16% mentioned little. Thirty-seven % of the respondents didn’t know.
Whereas a bigger share of officers from the most important firms mentioned they received most or a few of the rebates, the solutions — and their distinction with the testimony of PBM leaders — mirror the confusion or ignorance of employers about what their drug profit managers do, mentioned survey chief Gary Claxton, a senior vice chairman at KFF, a well being data nonprofit that features KFF Well being Information.
“I don’t suppose they’ll ever know all of the methods the cash strikes round as a result of there are such a lot of layers, between the wholesalers and the pharmacies and the producers,” he mentioned…“Employers are typically annoyed by the dearth of transparency into all the costs on the market,” Claxton mentioned. “They will’t really know what’s true.”
Do you suppose PBMs result in larger or decrease pharmacy value?
